Anniella Isgren

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Cerebrospinal fluid biomarkers reveal transdiagnostic synaptic dysfunction across major psychiatric disorders.

Cerebrospinal fluid biomarkers reveal transdiagnostic synaptic dysfunction across major psychiatric disorders.

Journal: Nature communications

Published: October 22, 2025

Lower complement C1q levels in first-episode psychosis and in schizophrenia.

Lower complement C1q levels in first-episode psychosis and in schizophrenia.

Journal: Brain, behavior, and immunity

Published: September 27, 2023

Cerebrospinal fluid proteomic study of two bipolar disorder cohorts.

Cerebrospinal fluid proteomic study of two bipolar disorder cohorts.

Journal: Molecular psychiatry

Published: February 01, 2022

Cerebrospinal fluid concentration of complement component 4A is increased in first episode schizophrenia.

Cerebrospinal fluid concentration of complement component 4A is increased in first episode schizophrenia.

Journal: Nature communications

Published: September 02, 2021

A serum proteomic study of two case-control cohorts identifies novel biomarkers for bipolar disorder.

A serum proteomic study of two case-control cohorts identifies novel biomarkers for bipolar disorder.

Journal: Translational psychiatry

Published: July 12, 2021

Cerebrospinal fluid proteomics targeted for central nervous system processes in bipolar disorder.

Cerebrospinal fluid proteomics targeted for central nervous system processes in bipolar disorder.

Journal: Molecular psychiatry

Published: December 22, 2020

Genome-wide study of immune biomarkers in cerebrospinal fluid and serum from patients with bipolar disorder and controls.

Genome-wide study of immune biomarkers in cerebrospinal fluid and serum from patients with bipolar disorder and controls.

Journal: Translational psychiatry

Published: August 11, 2019

Prevalences of autoimmune diseases in schizophrenia, bipolar I and II disorder, and controls.

Prevalences of autoimmune diseases in schizophrenia, bipolar I and II disorder, and controls.

Journal: Psychiatry research

Published: March 10, 2017

Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes.

Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes.

Journal: Brain, behavior, and immunity

Published: March 07, 2017

Prescribed drug use for bipolar disorder type I and II in clinical practice

Prescribed drug use for bipolar disorder type I and II in clinical practice

Journal: Lakartidningen

Published: January 18, 2017

Monocyte and microglial activation in patients with mood-stabilized bipolar disorder.

Monocyte and microglial activation in patients with mood-stabilized bipolar disorder.

Journal: Journal of psychiatry & neuroscience : JPN

Published: March 14, 2015

CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment.

CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: January 21, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026